Vasyl Eisenberg

Bar-Ilan University — Israel

Biochemistry, Genetics and Molecular Biology · Life Sciences

5h-index984citations10works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glycosylation and Glycoproteins Research(5), Immunotherapy and Immune Responses(4), Monoclonal and Polyclonal Antibodies Research(4), Immune Cell Function and Interaction(4), CAR-T cell therapy research(4)

Publications10 total

Figure S4 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Data from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Figure S1 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Figure S3 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Figure S2 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
Cancer Immunology Research·2024· 8 cited
A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
Journal for ImmunoTherapy of Cancer·2019· 78 citedOpen Access
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
Nature·2019· 848 citedOpen Access
T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer
Advanced Drug Delivery Reviews·2019· 26 cited
Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor
Frontiers in Immunology·2017· 24 citedOpen Access

Frequent Co-authors

Cyrille J. Cohen(10), Shiran Hoogi(9), Erel Katzman(6), Nimrod Ben Haim(6), Raphaelle Zur-Toledano(6), Maria Radman(6), Yishai Reboh(6), Oranit Zadok(6), Iris Kamer(6), Jair Bar(6), Irit Sagi(6), Ayal Hendel(6), Astar Shamul(2), Tilda Barliya(2), Francesca Alfei(1), Kristiyan Kanev(1), Maike Hofmann(1), Ming Wu(1), Hazem E. Ghoneim(1), Patrick Roelli(1)